OncoMatch/Clinical Trials/NCT06463522
Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma
Is NCT06463522 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies non-drug interventions for hepatocellular carcinoma.
This is a Phase 1, open label clinical trial of tumor-infiltrating lymphocytes for the treatment of patients with hepatocellular carcinoma. The purpose of this study is to assess the safety of tumor-infiltrating lymphocytes therapy in patients with hepatocellular carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: immune cell therapy (CIK, DC, DC-CIK, LAK therapy)
Exception: allowed if >28 days since last treatment
Subjects who have previously used immune cell therapy (CIK, DC, DC-CIK, LAK therapy) and are less than 28 days from the end of treatment to screening
Lab requirements
Blood counts
Absolute neutrophil count >1.0 x 10^9/L; White blood cell count > 2.0 x 10^9/L; Platelet count > 60 x 10^9/L; Hgb > 8.0 g/dL
Liver function
Liver function grade Child-Pugh A or B, without hepatic encephalopathy; ALT and AST ≤ 5x ULN; Serum total bilirubin (TBiL) ≤ 51 mmol/L, or < 3x ULN
Cardiac function
Left ventricular ejection fraction (LVEF) ≥ 50%
Liver function grade Child-Pugh A or B, without hepatic encephalopathy; Absolute neutrophil count >1.0 x 10^9/L; White blood cell count > 2.0 x 10^9/L; Platelet count > 60 x 10^9/L; Hgb > 8.0 g/dL; ALT and AST ≤ 5 times the upper limit of normal (ULN), Serum total bilirubin (TBiL) ≤ 51 mmol/L, or < 3 times the ULN; Left ventricular ejection fraction (LVEF) ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06463522 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immune cell therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages